Richard Segal

Cooley advised the underwriters in Karuna Therapeutics’ $862.5 million follow-on offering of 4,011,628 shares of common stock at a public offering price of $215 per share. Karuna is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Partners Richard Segal, Jean Park, Div Gupta and associate Darah Protas led the Cooley team.

Cooley advised the underwriters in Verve Therapeutics’ $258.8 million follow-on offering of 9,583,334 shares of common stock at a public offering price of $27 per share. Verve is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene-editing medicines. Partners Rich Segal and Div Gupta, and associate Darah Protas, led the Cooley team.

Cooley advised underwriters on EyePoint Pharmaceuticals’ $115.4 million follow-on offering, with Cowen and Guggenheim Securities acting as joint bookrunning managers. EyePoint Pharmaceuticals is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. Partners Rich Segal and Daniel Goldberg led the Cooley team.

Cooley advised the underwriters in Zentalis Pharmaceuticals’ $200 million follow-on offering of 10,330,000 shares of common stock at an offering price of $19.38 per share. Zentalis is a clinical-stage biopharmaceutical company developing small-molecule therapeutics targeting fundamental biological pathways of cancers. Partners Richard Segal and Div Gupta led the Cooley team.

Cooley advised the underwriters on The Clorox Company’s registered debt offering of $1.1 billion aggregate principal amount of investment grade unsecured senior notes. The offering consisted of $500 million of 4.400% senior notes due 2029 and $600 million of 4.600% senior notes due 2032. Partners Eric Blanchard and Richard Segal, and associates Evan Leitner, Matthew Kosior and Olivia Creser, led the Cooley team advising the underwriters.